Live Feeds
● TRACKER Updated 26d ago · 9 sources tracked

Moderna and Merck shares soar on mRNA cancer vaccine

Moderna and Merck developed an mRNA cancer vaccine that prevents melanoma from returning, according to results from a large late-stage trial. The success triggered a surge in share prices for both companies, with Moderna stock jumping between 90% and 160%. This price spike caused an estimated $5 billion loss for investors betting against the stock. The breakthrough suggests a potential new wave of mRNA-based treatments for various types of cancer beyond skin cancer.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ A late-stage trial showed a Moderna and Merck mRNA vaccine prevents melanoma from returning.
  • ✓ Moderna and Merck shares increased following the trial results.
  • ✓ Moderna stock experienced a surge of 90% to 160%.
🛡️ Source Corroboration: 9 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Late-stage trial results show the Moderna-Merck vaccine prevents melanoma recurrence and spread.

Live updates

  1. Moderna and Merck mRNA Vaccine Prevents Melanoma Recurrence in Late-Stage Trial

    Moderna and Merck developed an mRNA cancer vaccine that prevents melanoma from returning, according to results from a large late-stage trial. The success triggered a surge in share prices for both companies, with Moderna stock jumping between 90% and 160%. This price spike caused an estimated $5 billion loss for investors betting against the stock. The breakthrough suggests a potential new wave of mRNA-based treatments for various types of cancer beyond skin cancer.

    Why it matters

    mRNA technology gained global prominence during the COVID-19 pandemic. Applying this platform to oncology allows for personalized vaccines that target specific cancer markers. Success in melanoma trials provides a proof-of-concept for treating other solid tumors.

    What is confirmed

    • A late-stage trial showed a Moderna and Merck mRNA vaccine prevents melanoma from returning.
    • Moderna and Merck shares increased following the trial results.
    • Moderna stock experienced a surge of 90% to 160%.

    Still unconfirmed

    • Short sellers suffered a $5 billion loss due to the Moderna stock surge.
    • The vaccine could reduce the spread of skin cancer.

    What to watch next

    • FDA filing or approval timeline for the melanoma vaccine
    • Trial results for the vaccine against other cancer types
    • Updated financial reports on the impact of the stock surge
    Sources used for this update (9)
    1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    2. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
    3. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
    4. cnn.com — Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
    5. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    6. Axios — Moderna and Merck shares soar on mRNA cancer vaccine
    7. Financial Times — Moderna pins hopes on mRNA ‘game-changer’ for cancer vaccines
    8. NPR — New mRNA vaccine could reduce the recurrence and spread of skin cancer
    9. Yahoo Finance — Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today?
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community